HRP20171773T1 - Kristalični oblik od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona i njegova uporaba kao antagonisti receptora oreksina - Google Patents
Kristalični oblik od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona i njegova uporaba kao antagonisti receptora oreksina Download PDFInfo
- Publication number
- HRP20171773T1 HRP20171773T1 HRP20171773TT HRP20171773T HRP20171773T1 HR P20171773 T1 HRP20171773 T1 HR P20171773T1 HR P20171773T T HRP20171773T T HR P20171773TT HR P20171773 T HRP20171773 T HR P20171773T HR P20171773 T1 HRP20171773 T1 HR P20171773T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- compound
- triazol
- imidazol
- benzo
- Prior art date
Links
- NBGABHGMJVIVBW-QHCPKHFHSA-N [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound N1([C@](CCC1)(C)C=1NC2=CC=C(Cl)C(C)=C2N=1)C(=O)C1=CC(OC)=CC=C1N1N=CC=N1 NBGABHGMJVIVBW-QHCPKHFHSA-N 0.000 title claims 18
- 229940123730 Orexin receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- 238000010586 diagram Methods 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000005855 radiation Effects 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010013980 Dyssomnias Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000006199 Parasomnias Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000011067 equilibration Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (16)
1. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona, naznačen time, da:
• pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 8,6°, 15,2° i 21,3°; ili
• pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 13,4°, 18,3° i 24,0°.
2. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevu 1, naznačen time, da pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 8,6°, 15,2°, i 21,3°, gdje se navedeni dijagram difrakcije praha X-zraka dobiva pomoću kombinirane radijacije Cu Kα1 i Cu Kα2, bez Kα2-strippinga; a preciznost za 2θ-vrijednosti leži u rasponu od 2θ +/- 0,2°.
3. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevu 1, naznačen time, da pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 8,6°, 11,5°, 13,4°, 14,6°, 15,2°, 15,5°, 19,3°, 21,3°, 22,4°, i 26,4°, gdje se navedeni dijagram difrakcije praha X-zraka dobiva pomoću kombinirane radijacije Cu Kα1 i Cu Kα2, bez Kα2-strippinga; a preciznost za 2θ-vrijednosti leži u rasponu od 2θ +/- 0,2°.
4. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevima 2 ili 3, naznačen time, da u biti pokazuje uzorak difrakcije praha X-zraka kao što je prikazano na Slici 2.
5. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 2 do 4, naznačen time, da navedeni kristalični oblik je polu-hidrat.
6. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 2 do 5, naznačen time, da se dobiva pomoću sljedećeg:
a) miješanje 2 g SPOJA kao amorfnog materijala s 8 mL smjese etanol/voda u omjeru 1/4 (volumen/volumen);
b) dodavanje oko 0,05 g kristalnih zrnaca SPOJA u kristaličnom obliku 1;
c) protresanje uz brzinu od 300 rpm u trajanju oko 16 sati na sobnoj temperaturi;
d) filtriranje i ispiranje čvrste grude s 2 mL smjese etanol/voda u omjeru 1/4 (v/v) i sušenje proizvoda na sobnoj temperaturi i uz smanjeni tlak od oko 10 mbara u trajanju od 4 sata; i
e) otvoreno ekvilibriranje na sobnoj temperaturi i uz oko 60% relativne vlažnosti u trajanju od 2 sata.
7. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevu 1, naznačen time, da pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 13,4°, 18,3°, i 24,0°, gdje se navedeni dijagram difrakcije praha X-zraka dobiva pomoću kombinirane radijacije Cu Kα1 i Cu Kα2, bez Kα2-strippinga; a preciznost za 2θ-vrijednosti leži u rasponu od 2θ +/- 0,2°.
8. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevu 1, naznačen time, da pokazuje vršne vrijednosti u difrakcijskom dijagramu praha X-zraka, uz sljedeće refrakcijske kutove 2θ: 10,9°, 13,4°, 14,3°, 14,9°, 18,3°, 20,9°, 21,1°, 21,8°, 24,0°, i 30,1°, gdje se navedeni dijagram difrakcije praha X-zraka dobiva pomoću kombinirane radijacije Cu Kα1 i Cu Kα2, bez Kα2-strippinga; a preciznost za 2θ-vrijednosti leži u rasponu od 2θ +/- 0,2°.
9. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema zahtjevima 7 ili 8, naznačen time, da u biti pokazuje uzorak difrakcije praha X-zraka kao što je prikazano na Slici 3.
10. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 7 do 9, naznačen time, da navedeni kristalični oblik je anhidrat.
11. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 7 do 10, naznačen time, da se dobiva pomoću sljedećeg:
a) miješanje 10 mg SPOJA u kristaličnom obliku 1 u 0,05 mL acetonitrila;
b) miješanje u zatvorenoj fijali od 4 mL u trajanju do tri dana;
c) izolacija; i sušenje uz smanjeni tlak na sobnoj temperaturi u trajanju od 2 sata.
12. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 1 do 11, naznačen time, da se upotrebljava kao lijek.
13. Farmaceutski sastav, naznačen time, da kao djelotvorni sastojak obuhvaća kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 1 do 11, i najmanje jedan farmaceutski prikladan nosač.
14. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 1 do 11, naznačen time, da se upotrebljava u proizvodnji farmaceutskog sastava, pri čemu navedeni farmaceutski sastav, kao djelotvorni sastojak obuhvaća spoj (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona, i najmanje jedan farmaceutski prikladan materijal za nosač.
15. Kristalični oblik spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 1 do 11, ili farmaceutski sastav prema zahtjevu 13, naznačen time, da se upotrebljava u liječenju ili prevenciji bolesti ili poremećaja odabranih iz skupine koju čine: poremećaji spavanja odabrani iz skupine koja se sastoji od disomnija, parasomnija, poremećaja spavanja povezanih s općim medicinskim stanjem i poremećaja spavanja izazvanih supstancama; poremećaj anksioznosti; i poremećaj ovisnosti.
16. Uporaba kristaličnog oblika spoja (S)-(2-(6-kloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanona prema bilo kojem od zahtjeva 1 do 11, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti ili poremećaja odabranih iz skupine koju čine: poremećaji spavanja, poremećaji anksioznosti, poremećaji ovisnosti, kognitivne disfunkcije, poremećaji raspoloženja, i poremećaji teka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013060596 | 2013-12-03 | ||
| PCT/IB2014/066508 WO2015083070A1 (en) | 2013-12-03 | 2014-12-02 | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| EP14824107.8A EP3077389B1 (en) | 2013-12-03 | 2014-12-02 | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171773T1 true HRP20171773T1 (hr) | 2017-12-29 |
Family
ID=52282786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171773TT HRP20171773T1 (hr) | 2013-12-03 | 2017-11-16 | Kristalični oblik od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona i njegova uporaba kao antagonisti receptora oreksina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9914720B2 (hr) |
| EP (1) | EP3077389B1 (hr) |
| JP (1) | JP6496733B2 (hr) |
| KR (1) | KR102361418B1 (hr) |
| CN (1) | CN105793257B (hr) |
| AU (1) | AU2014358742B2 (hr) |
| CA (1) | CA2929423C (hr) |
| CL (1) | CL2016001342A1 (hr) |
| CY (1) | CY1119695T1 (hr) |
| DK (1) | DK3077389T3 (hr) |
| EA (1) | EA030137B1 (hr) |
| ES (1) | ES2651475T3 (hr) |
| HK (1) | HK1225731B (hr) |
| HR (1) | HRP20171773T1 (hr) |
| HU (1) | HUE035731T2 (hr) |
| IL (1) | IL245923B (hr) |
| LT (1) | LT3077389T (hr) |
| MA (1) | MA39163B1 (hr) |
| MX (1) | MX364208B (hr) |
| MY (1) | MY179862A (hr) |
| NO (1) | NO3077389T3 (hr) |
| NZ (1) | NZ721438A (hr) |
| PH (1) | PH12016500988B1 (hr) |
| PL (1) | PL3077389T3 (hr) |
| PT (1) | PT3077389T (hr) |
| SA (1) | SA516371231B1 (hr) |
| SI (1) | SI3077389T1 (hr) |
| TW (1) | TWI664177B (hr) |
| UA (1) | UA119549C2 (hr) |
| WO (1) | WO2015083070A1 (hr) |
| ZA (1) | ZA201604499B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| CN105873921B (zh) | 2013-12-04 | 2019-03-15 | 爱杜西亚药品有限公司 | 苯并咪唑-脯氨酸衍生物的用途 |
| PL3619199T3 (pl) | 2017-05-03 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)-benzoesowego |
| IL297234A (en) | 2020-04-19 | 2022-12-01 | Idorsia Pharmaceuticals Ltd | Medical use of deridorxant |
| KR20230142554A (ko) * | 2021-02-02 | 2023-10-11 | 메드샤인 디스커버리 아이엔씨. | 테트라하이드로피롤로사이클릭 화합물 및 이의 용도 |
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
| AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| ATE286897T1 (de) | 2000-11-28 | 2005-01-15 | Smithkline Beecham Plc | Morpholinderivate als antagonisten an orexinrezeptoren |
| KR20030096348A (ko) | 2001-05-05 | 2003-12-24 | 스미스클라인비이참피이엘시이 | Ｎ-아로일 시클릭 아민 |
| EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン誘導体 |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| AU2003262516A1 (en) | 2002-09-18 | 2004-04-08 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| PT1751111E (pt) | 2004-03-01 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina substituída |
| BRPI0708913A2 (pt) | 2006-03-15 | 2011-06-14 | Actelion Pharmaceuticals Ltd | uso de compostos derivados de tetraidroisoquinolina para aumentar a funÇço da memària |
| WO2007135527A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
| RU2447070C2 (ru) | 2006-08-15 | 2012-04-10 | Актелион Фармасьютиклз Лтд | Соединения азетидина в качестве антагонистов рецептора орексина |
| EP2079690B1 (en) | 2006-09-29 | 2010-09-15 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.1.0]hexane derivatives |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| CN101711247A (zh) | 2007-05-14 | 2010-05-19 | 埃科特莱茵药品有限公司 | 2-环丙基-噻唑衍生物 |
| EP2150115B1 (en) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| US20090022670A1 (en) | 2007-07-03 | 2009-01-22 | Giuseppe Alvaro | Novel compounds |
| CA2691373A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| ATE493386T1 (de) | 2007-07-27 | 2011-01-15 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate |
| CA2693820A1 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| WO2009040730A2 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| US8236801B2 (en) | 2008-02-21 | 2012-08-07 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CN102083827A (zh) | 2008-07-07 | 2011-06-01 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的噻唑烷化合物 |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
| MX2011005799A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
| GB0823467D0 (en) * | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| SG175026A1 (en) | 2009-04-24 | 2011-11-28 | Glaxo Group Ltd | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
| TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| CN103201261A (zh) | 2010-11-10 | 2013-07-10 | 埃科特莱茵药品有限公司 | 用作为食欲素受体拮抗剂的内酰胺衍生物 |
| ES2541531T3 (es) | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
| WO2013068935A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| TWI570120B (zh) * | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| CA2885180C (en) | 2012-10-10 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| CN105873921B (zh) | 2013-12-04 | 2019-03-15 | 爱杜西亚药品有限公司 | 苯并咪唑-脯氨酸衍生物的用途 |
-
2014
- 2014-12-02 DK DK14824107.8T patent/DK3077389T3/da active
- 2014-12-02 MY MYPI2016701997A patent/MY179862A/en unknown
- 2014-12-02 TW TW103141828A patent/TWI664177B/zh active
- 2014-12-02 LT LTEP14824107.8T patent/LT3077389T/lt unknown
- 2014-12-02 WO PCT/IB2014/066508 patent/WO2015083070A1/en active Application Filing
- 2014-12-02 ES ES14824107.8T patent/ES2651475T3/es active Active
- 2014-12-02 JP JP2016536109A patent/JP6496733B2/ja active Active
- 2014-12-02 NZ NZ721438A patent/NZ721438A/en unknown
- 2014-12-02 CA CA2929423A patent/CA2929423C/en active Active
- 2014-12-02 PL PL14824107T patent/PL3077389T3/pl unknown
- 2014-12-02 UA UAA201607114A patent/UA119549C2/uk unknown
- 2014-12-02 AU AU2014358742A patent/AU2014358742B2/en active Active
- 2014-12-02 NO NO14824107A patent/NO3077389T3/no unknown
- 2014-12-02 EP EP14824107.8A patent/EP3077389B1/en active Active
- 2014-12-02 US US15/101,768 patent/US9914720B2/en active Active
- 2014-12-02 MA MA39163A patent/MA39163B1/fr unknown
- 2014-12-02 HU HUE14824107A patent/HUE035731T2/hu unknown
- 2014-12-02 MX MX2016007215A patent/MX364208B/es active IP Right Grant
- 2014-12-02 EA EA201600435A patent/EA030137B1/ru not_active IP Right Cessation
- 2014-12-02 CN CN201480065274.7A patent/CN105793257B/zh active Active
- 2014-12-02 SI SI201430489T patent/SI3077389T1/en unknown
- 2014-12-02 KR KR1020167017644A patent/KR102361418B1/ko active IP Right Grant
- 2014-12-02 PT PT148241078T patent/PT3077389T/pt unknown
-
2016
- 2016-05-26 PH PH12016500988A patent/PH12016500988B1/en unknown
- 2016-05-30 IL IL245923A patent/IL245923B/en active IP Right Grant
- 2016-05-30 SA SA516371231A patent/SA516371231B1/ar unknown
- 2016-06-02 CL CL2016001342A patent/CL2016001342A1/es unknown
- 2016-07-01 ZA ZA2016/04499A patent/ZA201604499B/en unknown
- 2016-12-13 HK HK16114145A patent/HK1225731B/zh unknown
-
2017
- 2017-11-16 HR HRP20171773TT patent/HRP20171773T1/hr unknown
- 2017-12-12 CY CY20171101301T patent/CY1119695T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171773T1 (hr) | Kristalični oblik od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona i njegova uporaba kao antagonisti receptora oreksina | |
| CN105899505B (zh) | 用于治疗自身免疫病症的吡唑 | |
| HRP20171772T1 (hr) | Kristalični oblik soli od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona koji služi kao antagonist receptora oreksina | |
| CN105683166B (zh) | 取代的嘧啶Bmi-1抑制剂 | |
| CN101679413B (zh) | 3-([1,2,4]三唑[4,3-a]吡啶-7-基)苯甲酰胺衍生物 | |
| AU2023203860A1 (en) | Modulators of the integrated stress pathway | |
| JP2016539136A5 (hr) | ||
| HRP20171620T1 (hr) | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol | |
| BR112020008825A2 (pt) | moduladores da via de estresse integrada | |
| KR20220016467A (ko) | 통합된 스트레스 경로의 조절인자로서 치환된 사이클로알킬 | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| HUE026446T2 (en) | 5-membered heterocyclic amides and related compounds | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| BRPI0816219B8 (pt) | compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso | |
| CO6612185A2 (es) | Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos | |
| MX2009008323A (es) | Derivados heterociclicos como receptores muscarinicos m3. | |
| WO2013050938A1 (en) | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives | |
| EP4139287A1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| TW201321371A (zh) | 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物 | |
| CN106478621B (zh) | 喹啉或喹唑啉类衍生物、制备方法及其应用 | |
| CA2720490A1 (en) | Compounds and compositions as itpkb inhibitors | |
| JP2015504864A (ja) | ピペラジン誘導体およびｍＧｌｕ５受容体のポジティブアロステリックモジュレーターとしてのその使用 | |
| CA2813063A1 (en) | Antagonist for mutated androgen receptor | |
| ES2672737T3 (es) | Derivados de diazepinona útiles para el tratamiento del síndrome de X frágil, enfermedad de Parkinson o reflujo |